Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07105228 · ClinicalTrials.gov registry record
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 290,000
- Enrollment target
NCT07105228: Completed study, sponsored by Regeneron Pharmaceuticals.
NCT07105228 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 290,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07105228 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 290,000 participants
- Enrollment target
Study Summary
This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice. The main objective is to describe demographic and clinical characteristics of patients receiving aflibercept 2mg injections, to estimate the incidence of RV and RV plus Intraocular Inflammation (IOI) following aflibercept 2mg injections and to describe characteristics of RV cases.
Primary Outcome
Incidence will be defined as the number of events during the at-risk period divided by the total number of injections, identified using international classification of diseases (ICD-10) diagnosis codes
Interventions
- DRUG aflibercept 2mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290,000 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2025-09-15 |
What the finished NCT07105228 record still lists
NCT07105228 is an observational study that tracks outcomes without assigning an intervention. Its 290,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which aflibercept 2mg is the first listed.
NCT07105228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07105228 about?
NCT07105228 is a clinical study titled "Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study". This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice. The main objective is to describe demographic and clinical characteristics of pat...
What is the current status of trial NCT07105228?
This trial is currently completed. The enrollment target is 290,000 participants. The study started on 2025-07-15. Estimated completion is 2025-09-15.
What interventions are being tested in trial NCT07105228?
The interventions under investigation include: aflibercept 2mg (DRUG).
Who is sponsoring clinical trial NCT07105228?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
- NCT07314697 · 300,000 participants · NA
Arrival Time Implementation
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI